RT Journal Article
SR Electronic
T1 Performance profile of FDG-PET and PET/CT for cancer screening on the basis of a Japanese nationwide survey between 2005 and 2007
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1372
OP 1372
VO 50
IS supplement 2
A1 Minamimoto, Ryogo
A1 Senda, Michio
A1 Uno, Kimiichi
A1 Jinnouchi, Seishi
A1 Fukuda, Hiroshi
A1 Inoue, Tomio
YR 2009
UL http://jnm.snmjournals.org/content/50/supplement_2/1372.abstract
AB 1372 Objectives “FDG-PET for cancer screening” was defined as performed FDG-PET or PET/CT with or without combination of other tests for cancer screening of healthy subjects. The aim of this study is to survey the situation of “FDG-PET for cancer screening” in Japan and to clarify its performance profile. Methods Questionnaires regarding FDG-PET cancer screening were sent to 179 facilities in which FDG-PET tests were performed between 2005 and 2007. We evaluated 126385 subjects from 91PET centers, who were positive by FDG-PET and/or by one or more combined screening tests and were referred for further evaluation. Results On analyzing 126385 cases in detail from 91 PET centers thorough examination was indicated for 10.3% (9.1% for dedicated PET, 11.1% for PET/CT) of the cases as a result of positive findings in PET and/or combined test. Among those, 1483 cases of cancers (1.17% of total cases, positive predictive value of 30.3%) were found, of which 0.92% were PET positive and 0.26% were PET negative, resulting in the relative sensitivity of PET being 78.1%. Cancers of the colon/rectum, thyroid, lung, and breast were most frequently found (317, 288, 251, and 117 cases, respectively) with high PET sensitivity (86%, 90%, 82%, and 87% ). Conclusions We evaluated the performance profile of “FDG-PET for cancer screening” on the basis of a Japanese nationwide survey. It made a great contribution to detect a variety of cancers. Research Support This research was supported by a Health and Labor Sciences Research Grant for the project titled “Third-Term Comprehensive Control Research for Cancer” from the Ministry of Health, Labor, and Welfare, Japan.